Tag: AavantiBio

Mergers and Acquisitions

Solid Biosciences acquires AavantiBio, conducts $75 million private placement

October 4, 2022

Via: Pharmaphorum

AavantiBio, a precision genetic medicine company that was bankrolled by Solid’s rival Sarepta back in 2020, focuses on neuromuscular and cardiac rare diseases. Its key assets include product candidates for Duchenne muscular dystrophy (DMD), Friedreich’s ataxia, and BAG3 mediated dilated […]